Compounds in 'monster' radish could help tame cardiovascular disease

Step aside carrots, onions and broccoli. The newest heart-healthy vegetable could be a gigantic, record-setting radish. In a study appearing in ACS' Journal of Agricultural and Food Chemistry, scientists report that compounds found in the Sakurajima Daikon, or "monster," radish could help protect coronary blood vessels and potentially prevent heart disease and stroke. The finding could lead to the discovery of similar substances in other vegetables and perhaps lead to new drug treatments.

Grown for centuries in Japan, the Sakurajima Daikon is one of the Earth's most massive vegetables. In 2003, the Guinness Book of World Records certified a Sakurajima weighing nearly 69 pounds as the world's heaviest radish. Radishes are good sources of antioxidants and reportedly can reduce high blood pressure and the threat of clots, a pair of risk factors for heart attack and stroke. But to date, no studies have directly compared the heart-health benefits of the Sakurajima Daikon to other radishes. To address this knowledge gap, Katsuko Kajiya and colleagues sought to find out what effects this radish would have on nitric oxide production, a key regulator of coronary blood vessel function, and to determine its underlying mechanisms.

The researchers exposed human and pig vascular endothelial cells to extracts from Sakurajima Daikon and smaller radishes. Using fluorescence microscopy and other analytical techniques, the research team found the Sakurajima Daikon radish induced more nitric oxide production in these vascular cells than a smaller Japanese radish. They also identified trigonelline, a plant hormone, as the active component in Sakurajima Daikon that appears to promote a cascade of changes in coronary blood vessels resulting improved nitric oxide production.

Rei Kuroda, Kimiko Kazumura, Miki Ushikata, Yuji Minami, Katsuko Kajiya.
Elucidating the Improvement in Vascular Endothelial Function from Sakurajima Daikon and Its Mechanism of Action: A Comparative Study with Raphanus sativus.
J. Agric. Food Chem., doi: 10.1021/acs.jafc.8b01750.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...